Does holding at 12.5 mg for twelve weeks before escalating reduce constipation?

Concretely: 12.5 mg · twelve weeks · constipation.

I want to know whether this is a real physical effect or an artefact of how it is measured.

What prompted the question is an inconsistency between two sources I otherwise trust.

Why does this happen, and what would falsify the usual explanation?

twelve weeks at 12.5 mg is 84 days at one dose level — and the arithmetic the question hides is that it also moves every dose above 12.5 mg back by 84 days. Whether that reduces constipation depends on which quantity it tracks. A symptom driven by the dose itself is unchanged by waiting: 12.5 mg is 12.5 mg on day 1 and on day 84. A symptom driven by the rate of change has 84 days of no change to settle in, which is the case the hold is actually made for. The distinction is testable on your own record: plot constipation against days-since-last-increase rather than against dose, and if the peaks line up with the increases the hold is doing something. Escalation schedules are set by a prescriber, and nothing here is medical advice.

Answering this needs the agent and the current step, since the schedules differ and the reason they differ is pharmacokinetic.

The published semaglutide weight-management schedule steps 0.25, 0.5, 1.0, 1.7 and 2.4 mg at four-week intervals, with 0.25 mg as an initiation step rather than a therapeutic one.

Label titration ladders, structure only

Structure is identical across the class: small start, four-week steps, a defined maintenance range, a defined ceiling.

Escalating while gastrointestinal symptoms are still active is the commonest avoidable error. Tolerance to the previous step has not developed, and the new step lands on top of it.

Four to five half-lives to steady state is standard first-order pharmacokinetics and gives the four-week interval directly from the one-week half-life.

Faster titration does not reach the destination sooner in any way that matters; it reaches the symptoms sooner.

The top of the schedule is not the target. The working dose is.

The relevant arithmetic is that steady state takes four to five half-lives, so a one-week half-life means a four-week step interval and nothing shorter is informative.

The dose that produces an acceptable result with acceptable tolerability is the endpoint, not the top of the schedule. A substantial fraction of trial participants did well below the maximum.

For an agent with a one-week half-life, steady state after a dose change is reached in about four to five weeks. Escalating at two weeks means escalating from a position you have not yet reached, and the resulting exposure is higher than the schedule intends.

A schedule described here is a published schedule for a licensed product and is not a recommendation.

Stepping back is a normal adjustment, not a failure.

Start with the half-life, because the interval between steps should be at least four half-lives or you are escalating before the previous step has expressed itself.

The published tirzepatide schedule steps 2.5, 5, 7.5, 10, 12.5 and 15 mg at four-week intervals, with 2.5 mg as the initiation step rather than a therapeutic one.

Titrating downward is available too. Stepping back and holding is a normal adjustment rather than a failure.

Efficacy in the trials was dose-related but with substantial response at intermediate doses, which is why the maximum is not a target for everyone.

Hold rather than escalate while symptoms are active. Always.

This is the single most consequential controllable variable in the whole experience, and people routinely rush it.

Liraglutide titrates weekly rather than four-weekly because its half-life is about thirteen hours, so steady state is reached within days. The interval follows the pharmacokinetics in both cases.

Titration schedules in the licensed products were designed specifically to manage gastrointestinal tolerability, and that intent is stated in the clinical development literature.

Slower costs time and nothing else. The ceiling is the same.

edited 16 Nov 2024 by esther_vandeVelde — removed a claim I could not source

Answer first: the titration schedule exists to let tolerance to the gastrointestinal effects develop between steps, and every step in it is a tolerability decision rather than an efficacy one.

Holding a step for eight weeks instead of four is a legitimate approach with no efficacy cost at the destination, and it is what the trials effectively did for anyone who tolerated poorly.

Nothing here is medical advice, and research-use compounds are not approved for human use.

Four half-lives between steps, minimum. Work it out for your agent.